Bristol-Myers Squibb has tapped Duke University's in-house CRO to pitch in on clinical trial transparency, asking the organization's researchers to independently review requests for shared data.
Parexel figures it can rake in more than $2 billion in revenue in the next fiscal year, banking on a solid book-to-bill ratio and increasing global demand to deliver an all-time high.
As last week's BIO conference well illustrated, biotech companies go to great lengths to flaunt their assets in front of potential partners from Big Pharma. Global CRO Covance is developing a system it believes can make that process more efficient: an online platform that allows drug developers to securely list their up-for-license molecules for would-be collaborators.
Catalent and Perrigo will be able to sell generic versions of Teva's ProAir HFA inhaler starting in late 2016, resolving a patent dispute between the two parties.
Parexel International has reformatted its clinical trial management software, streamlining its services with an update the company believes can help its clients start studies faster.
Welsh CRO Simbec Research is expanding beyond its focus on early-phase studies, buying up Orion Clinical Services in a move the company says will make it a full-service organization.
Japan's CROèe, a patient-recruitment-focused contractor, has deepened its ties with partner BBK, launching a joint venture in the U.S. to provide a gateway into the country's growing market for drug development.
Quintiles believes in better drug sales through data analytics, signing a deal with a marketing-optimization company to pool resources and figure out how to better reach physicians on behalf of its commercialization clients.
Just three months after wrapping its latest merger, BioClinica has made another acquisition, snapping up Blueprint Clinical to expand its capabilities in the growing field of risk-based management.
A year removed from the $1.3 billion deal that made it a top-5 CRO, PRA has integrated its various acquisitions and is rebranding itself as a sprawling global drug development resourcer.
Novotech, which bills itself as Australia's largest CRO, has signed a deal with a South Korean outfit to help bolster the country's status among global drug development locales.
Quintiles, the world's largest CRO, is lending its Big Data heft to the American Physical Therapy Association, agreeing to help create a registry of patient outcomes data to inform future treatment.
Biotech Karyopharm Therapeutics has signed a deal with Veristat, recruiting the CRO to serve as a preferred partner as it develops a pipeline of first-in-class oncology treatments.
CRO inVentiv Health and biotech partner Oncobiologics have a plot to cash in on the burgeoning market for knockoffs of biotech drugs, and the two have begun development on a biosimilar of the blockbuster Humira.
Parexel International has approved a stock repurchase program of up to $150 million, and the company plans to use its existing cash and credit to buy up its own shares and boost investor value.
Four pharma service providers, led by MPI Research, have joined forces to form KPI Therapeutics, a new biotech designed to develop promising drug candidates and speed their way to market.
Lincoln, NE, CRO Celerion has opened up shop in Singapore, following through on its efforts to tap the fast-growing Asian market for clinical research.
Clinical trial software provider TrialScope has acquired most of Deloitte's life sciences analytics business, picking up a $5 million investment as it works to expand its share of the eClinical market.
Aprecia has an MIT-licensed method of 3-D printing pills and a plan to hit the market with easy-to-take formulations of top-selling medicines. To get there, the biotech has tapped CRO inVentiv Health, which is on hand to lend its commercialization expertise.